ES2158076T3 - Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores. - Google Patents

Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.

Info

Publication number
ES2158076T3
ES2158076T3 ES95904886T ES95904886T ES2158076T3 ES 2158076 T3 ES2158076 T3 ES 2158076T3 ES 95904886 T ES95904886 T ES 95904886T ES 95904886 T ES95904886 T ES 95904886T ES 2158076 T3 ES2158076 T3 ES 2158076T3
Authority
ES
Spain
Prior art keywords
compounds
sub
imidazolinylamine
chinolinics
alfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904886T
Other languages
English (en)
Inventor
Thomas Lee Cupps
Sophie Eva Bogdan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Application granted granted Critical
Publication of ES2158076T3 publication Critical patent/ES2158076T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EL OBJETO DE LA INVENCION CONCIERNE A LOS METODOS PARA EL TRATAMIENTO DE LA CONGESTION NASAL QUE CONSTA DE LA ADMINISTRACION A UN HUMANO O ANIMAL INFERIOR QUE NECESITE TAL TRATAMIENTO DE UNA CANTIDAD SEGURA Y EFICAZ DE UN COMPUESTO QUE TIENE LA ESTRUCTURA (I) EN LA QUE: (A) R ES ALCALINO O ALQUENILO C{SUB,1}-C{SUB,3} NO SUSTITUIDOS; Y (B) R SE SELECCIONA ENTRE HIDROGENO; ALCALINO O ALQUENILO C{SUB,1}-C{SUB,3} NO SUSTITUIDOS; ALQUILTIO O ALCOXIHALO. EL OBJETO DE LA INVENCION TAMBIEN CONCIERNE AL USO DE TALES COMPUESTOS PARA EVITAR O TRATAR OTROS TRASTORNOS RESPIRATORIOS, OCULARES Y/O GASTROINTESTINALES. EL OBJETO DE LA INVENCION TAMBIEN CONCIERNE A NUEVOS COMPUESTOS QUE TIENEN LA ESTRUCTURA ANTES MENCIONADA EN LA QUE R ES HIDROGENO, O FLUORO O CIANO.
ES95904886T 1993-12-17 1994-12-15 Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores. Expired - Lifetime ES2158076T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16934293A 1993-12-17 1993-12-17
US08/292,672 US5576437A (en) 1993-12-17 1994-08-18 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists

Publications (1)

Publication Number Publication Date
ES2158076T3 true ES2158076T3 (es) 2001-09-01

Family

ID=26864973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904886T Expired - Lifetime ES2158076T3 (es) 1993-12-17 1994-12-15 Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.

Country Status (23)

Country Link
US (2) US5576437A (es)
EP (1) EP0734261B1 (es)
JP (1) JPH09507219A (es)
CN (1) CN1085945C (es)
AT (1) ATE202475T1 (es)
AU (1) AU704857B2 (es)
BR (1) BR9408344A (es)
CA (1) CA2179011C (es)
CZ (1) CZ285990B6 (es)
DE (1) DE69427591T2 (es)
DK (1) DK0734261T3 (es)
ES (1) ES2158076T3 (es)
FI (1) FI962492A7 (es)
GR (1) GR3036199T3 (es)
HU (1) HU219494B (es)
NO (1) NO311749B1 (es)
NZ (1) NZ333369A (es)
PE (1) PE38095A1 (es)
PL (1) PL178054B1 (es)
SG (1) SG49111A1 (es)
SK (1) SK77296A3 (es)
TW (1) TW406077B (es)
WO (1) WO1995020386A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000069130A (ko) * 1996-11-25 2000-11-25 데이비드 엠 모이어 알파-2 아드레날린수용체 작용약으로서 유용한 구아니디닐아미노 헤테로사이클 화합물
US6306877B1 (en) 1999-08-09 2001-10-23 The Procter & Gamble Co. Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
US6172095B1 (en) 1996-11-25 2001-01-09 The Procter & Gamble Company Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists
SG72827A1 (en) * 1997-06-23 2000-05-23 Hoffmann La Roche Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
TW527355B (en) * 1997-07-02 2003-04-11 Bristol Myers Squibb Co Inhibitors of farnesyl protein transferase
JP2002543122A (ja) * 1999-04-30 2002-12-17 エイピーティー ファーマスーティカルズ エルエルスィー 抗マラリア治療剤についての新規使用
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
EP1744751A4 (en) * 2004-03-18 2010-03-10 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
CA2559282A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
DE102004049008A1 (de) * 2004-10-05 2006-04-06 Merck Patent Gmbh Neue Verwendung für α-Sympathomimetika mit 2-Imidazolinstruktur
BRPI0618643A2 (pt) 2005-11-09 2011-09-06 Combinatorx Inc composição compreendendo um par de fármacos, composição compreendendo um corticosteróide e um imunossupressor dependente de imunofilina não-esteróide, kits e uso
WO2009151683A2 (en) * 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
AU2009313927A1 (en) * 2008-11-13 2010-05-20 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
AU2012287164A1 (en) 2011-07-25 2014-02-20 Allergan, Inc. N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) * 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) * 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0086428B1 (en) * 1979-08-23 1987-07-29 Beecham Group Plc Antidiarrhoea veterinary composition, its production and oral doser containing it
WO1982000824A1 (en) * 1980-09-05 1982-03-18 Geissmann F 1h and 2h indazol derivatives and medicaments containing them
FR2638356A1 (fr) * 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) * 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) * 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Also Published As

Publication number Publication date
HU9601661D0 (en) 1996-08-28
CA2179011A1 (en) 1995-08-03
PE38095A1 (es) 1995-11-28
NO962537L (no) 1996-08-14
HUT76278A (en) 1997-07-28
NO311749B1 (no) 2002-01-21
US5716966A (en) 1998-02-10
DK0734261T3 (da) 2001-09-03
US5576437A (en) 1996-11-19
HU219494B (hu) 2001-04-28
FI962492A0 (fi) 1996-06-14
NZ333369A (en) 2001-04-27
FI962492L (fi) 1996-07-25
TW406077B (en) 2000-09-21
BR9408344A (pt) 1997-08-19
CA2179011C (en) 1999-11-30
CZ285990B6 (cs) 1999-12-15
GR3036199T3 (en) 2001-10-31
CN1137754A (zh) 1996-12-11
JPH09507219A (ja) 1997-07-22
CN1085945C (zh) 2002-06-05
AU1339495A (en) 1995-08-15
ATE202475T1 (de) 2001-07-15
DE69427591D1 (de) 2001-08-02
WO1995020386A1 (en) 1995-08-03
DE69427591T2 (de) 2002-04-25
EP0734261B1 (en) 2001-06-27
PL178054B1 (pl) 2000-02-29
PL315058A1 (en) 1996-09-30
NO962537D0 (no) 1996-06-14
CZ175296A3 (en) 1996-11-13
AU704857B2 (en) 1999-05-06
SK77296A3 (en) 1997-04-09
FI962492A7 (fi) 1996-07-25
SG49111A1 (en) 1998-05-18
EP0734261A1 (en) 1996-10-02

Similar Documents

Publication Publication Date Title
ES2158076T3 (es) Compuestos 7-(2-imidazolinilamino)quinolinicos utiles como agonistas de alfa-2 adrenoceptores.
ES2150546T3 (es) Compuestos de 6-(2-imidazolinilamino)quinoxalina utiles como agonistas de alfa-2-adrenoceptores.
ES2125377T3 (es) Azaheterociclicos triciclicos n-acilatados utiles como antagonistas de vasopresina.
AR002459A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
ES2119984T3 (es) Nuevos compuestos propinil bi-aromaticos, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
CO4900035A1 (es) Compuestos inhibidores de metaloproteasas 1,3-diheterocicli- cos, composiciones farmaceuticas que los contienen y metodos para utilizacion
TR200101096T2 (tr) Depolanmaya elverişli formoterol içeren etken madde konsantresi
AR016433A1 (es) Procedimiento para el tratamiento de la impotencia y composiciones.
ES2161886T3 (es) Composiciones en barra de gel que comprenden gelificantes opticamente enriquecidos.
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
CO4920240A1 (es) Compuestos inhibidores de metaloproteasa diheterociclicos, composiciones farmaceuticas que los contienen y metodos para su utilizacion
ES2163407T3 (es) Derivados piperidinilos tiaciclicos.
CL2008003938A1 (es) Uso de escitalopram o de una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento del desorden de estres postraumatico (divisional sol. 1799-00).
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
ES2116896B1 (es) Composicion estabilizante.
SE8703169D0 (sv) 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-3,4-dihydro-5h-2,3-benzodiazepine, acid addition salts thereof and process for preparing same
CO5011084A1 (es) Composiciones y metodos para tratar trastornos respiratorios
CO5160295A1 (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos cionalmente un ssri
PE20050393A1 (es) Compuestos de benzopirano para uso en el tratamiento y la prevencion de afecciones relacionadas con la inflamacion
EE04661B1 (et) Viirus-indutseeritud ssteemse šoki ja hingamispuudulikkuse reverseerimine lmfotoksiin-beeta raja blokeerimise abil
AR029588A1 (es) Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
ES2116411T3 (es) La sal sulfato de un triazol sustituido, composiciones farmaceuticas de la misma y su uso en terapia
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734261

Country of ref document: ES